Atrioventricular block adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 7,618 adverse event reports that record the MedDRA preferred term Atrioventricular block. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 378 reports in the 12 months to June 2026 and 403 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,132 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 378 (under 0.1%) record this term. Reports for patients 75 and over were 25.1% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 84 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Atrioventricular block name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetylsalicylic Acid		38
Aldactone	Aldosterone antagonist	46
Alprazolam	Benzodiazepine	51
Amiodarone		95
Amiodarone hcl		33
Amlodipine	Calcium channel blocker	110
Apixaban	Factor Xa inhibitor	32
Aricept	Cholinesterase inhibitor	33
Aspirin	Nonsteroidal anti-inflammatory drug	59
Atenolol	beta-Adrenergic blocker	84
Atorvastatin		34
Avandia		200
Bisoprolol	beta-Adrenergic blocker	285
Bisoprolol fumarate	beta-Adrenergic blocker	53
Brilinta	P2Y12 platelet inhibitor	43
Bumetanide	Loop diuretic	29
Candesartan	Angiotensin 2 receptor blocker	25
Carbamazepine	Mood stabilizer	34
Carvedilol	alpha-Adrenergic blocker	124
Celebrex	Nonsteroidal anti-inflammatory drug	31
Citalopram	Serotonin reuptake inhibitor	33
Clonazepam	Benzodiazepine	29
Cordarone		72
Cosentyx	Interleukin-17A antagonist	28
Cyclophosphamide	Alkylating drug	52
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	43
Dexamethasone	Corticosteroid	62
Digoxin	Cardiac glycoside	219
Diltiazem		63
Diltiazem hydrochloride	Calcium channel blocker	29
Donepezil		30
Dupixent	Interleukin-4 receptor alpha antagonist	37
Eliquis	Factor Xa inhibitor	49
Enbrel	Tumor necrosis factor blocker	35
Entresto	Angiotensin 2 receptor blocker	173
Escitalopram	Serotonin reuptake inhibitor	37
Flecainide		37
Furosemide	Loop diuretic	154
Gilenya	Sphingosine 1-phosphate receptor modulator	79
Humira		99
Hydroxychloroquine	Antimalarial	41
Ibuprofen	Nonsteroidal anti-inflammatory drug	29
Imbruvica	Kinase inhibitor	32
Lacosamide		67
Lamotrigine	Anti-epileptic agent	48
Lasix	Loop diuretic	26
Levetiracetam		49
Lexiscan(r) (regadenoson)		63
Lisinopril	Angiotensin converting enzyme inhibitor	50
Losartan	Angiotensin 2 receptor blocker	26
Lyrica		44
Metformin	Biguanide	87
Metoprolol	beta-Adrenergic blocker	160
Metoprolol succinate	beta-Adrenergic blocker	54
Metoprolol tartrate	beta-Adrenergic blocker	58
Midazolam	Benzodiazepine	29
Nivolumab	Programmed death Receptor-1 blocking antibody	41
Norvasc	Calcium channel blocker	26
Opdivo	Programmed death Receptor-1 blocking antibody	29
Pantoprazole	Proton pump inhibitor	40
Pantoprazole sodium	Proton pump inhibitor	25
Phenobarbital		35
Pradaxa	Direct thrombin inhibitor	40
Prednisone	Corticosteroid	54
Pregabalin		33
Propofol	General anesthetic	47
Propranolol	beta-Adrenergic blocker	59
Ramipril	Angiotensin converting enzyme inhibitor	97
Revlimid	Thalidomide analog	93
Rituximab	CD20-directed cytolytic antibody	40
Simvastatin	HMG-CoA reductase inhibitor	34
Sotalol	Antiarrhythmic	32
Spironolactone	Aldosterone antagonist	104
Symbicort	Corticosteroid	26
Tacrolimus	Calcineurin inhibitor immunosuppressant	37
Tamsulosin		27
Tamsulosin hydrochloride	alpha-Adrenergic blocker	26
Tiotropium bromide	Anticholinergic	31
Trulicity	GLP-1 receptor agonist	25
Verapamil		92
Verapamil hydrochloride	Calcium channel blocker	34
Vimpat		89
Vioxx		84
Xarelto	Factor Xa inhibitor	42

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 58 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Atrioventricular block name, in order of name
Class	Reports with this term
Aldosterone antagonist	170
Alkylating drug	53
alpha-Adrenergic blocker	186
Angiotensin 2 receptor blocker	366
Angiotensin converting enzyme inhibitor	181
Anti-epileptic agent	126
Antiarrhythmic	102
Anticholinergic	56
Antimalarial	67
Aromatase inhibitor	41
Atypical antipsychotic	170
Azole antifungal	36
Benzodiazepine	173
beta-Adrenergic blocker	853
Biguanide	109
Calcineurin inhibitor immunosuppressant	51
Calcium channel blocker	207
Cardiac glycoside	230
Catecholamine	31
CD20-directed cytolytic antibody	53
Central alpha-2 adrenergic agonist	40
Cholinesterase inhibitor	64
Corticosteroid	178
CTLA-4-directed blocking antibody	33
Cytomegalovirus nucleoside analog DNA polymerase inhibitor	26
Dihydropyridine calcium channel blocker	42
Direct thrombin inhibitor	40
Endothelin receptor antagonist	34
Factor Xa inhibitor	146
Fluoroquinolone antibacterial	25
General anesthetic	74
GLP-1 receptor agonist	48
HER2/neu receptor antagonist	30
Histamine-1 receptor antagonist	33
HMG-CoA reductase inhibitor	122
Insulin analog	63
Interleukin-17A antagonist	30
Interleukin-4 receptor alpha antagonist	46
Janus kinase inhibitor	54
Kinase inhibitor	171
Loop diuretic	228
Microtubule inhibitor	26
Mood stabilizer	74
Nonsteroidal anti-inflammatory drug	153
Nucleoside metabolic inhibitor	56
Opioid agonist	56
Osmotic laxative	45
P2Y12 platelet inhibitor	112
Platinum-based drug	43
Programmed death Receptor-1 blocking antibody	114
Proteasome inhibitor	33
Proton pump inhibitor	108
Serotonin reuptake inhibitor	155
Sodium-Glucose cotransporter 2 inhibitor	69
Sphingosine 1-phosphate receptor modulator	81
Thalidomide analog	119
Thiazide-like diuretic	30
Tumor necrosis factor blocker	71

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Atrioventricular block, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Atrioventricular block
Age	Reports	Share
Under 2	59	0.8%
2 to 11	50	0.7%
12 to 17	87	1.1%
18 to 44	578	7.6%
45 to 64	1,352	17.7%
65 to 74	1,374	18%
75 and over	1,912	25.1%
Age not given	2,206	29%

Sex of the patient in the reports that record Atrioventricular block
Sex	Reports	Share
Female	3,286	43.1%
Male	3,552	46.6%
Unknown or not given	780	10.2%

Age and sex are as the report gives them. 45.6% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Atrioventricular block: adverse event reports that record this term. https://reportedreactions.com/reaction/atrioventricular-block/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Atrioventricular block mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page